0.02(0.82%) Volume: 4,715,685 7:08PM EDT| Market Cap : 353.32 M | Enterprise Value : 78.62 M | P/E (TTM) : | P/B : 0.48 |
|---|
NAS:PDLI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:PDLI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| vs
industry |
vs
history |
||
|---|---|---|---|
| Cash-to-Debt | 3.27 |
PDLI's Cash-to-Debt is ranked lower than
66% of the 1078 Companies in the Global Biotechnology industry. ( Industry Median: 64.02 vs. PDLI: 3.27 ) Ranked among companies with meaningful Cash-to-Debt only. |
PDLI'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.25 Med: 1.84 Max: No Debt Current: 3.27 |
| Equity-to-Asset | 0.75 |
PDLI's Equity-to-Asset is ranked higher than
60% of the 763 Companies in the Global Biotechnology industry. ( Industry Median: 0.69 vs. PDLI: 0.75 ) Ranked among companies with meaningful Equity-to-Asset only. |
PDLI'
s Equity-to-Asset Range Over the Past 10 Years
Min: -1.93 Med: 0.62 Max: 0.98 Current: 0.75 |
| Debt-to-Equity | 0.17 |
PDLI's Debt-to-Equity is ranked higher than
64% of the 500 Companies in the Global Biotechnology industry. ( Industry Median: 0.28 vs. PDLI: 0.17 ) Ranked among companies with meaningful Debt-to-Equity only. |
PDLI'
s Debt-to-Equity Range Over the Past 10 Years
Min: -250.06 Med: 0.29 Max: 18.48 Current: 0.17 |
| Debt-to-EBITDA | -5.69 |
PDLI's Debt-to-EBITDA is ranked lower than
99.99% of the 196 Companies in the Global Biotechnology industry. ( Industry Median: 2.04 vs. PDLI: -5.69 ) Ranked among companies with meaningful Debt-to-EBITDA only. |
PDLI'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.69 Med: 1.12 Max: 2.65 Current: -5.69 |
| Interest Coverage | 5.10 |
PDLI's Interest Coverage is ranked lower than
91% of the 500 Companies in the Global Biotechnology industry. ( Industry Median: 10000.00 vs. PDLI: 5.10 ) Ranked among companies with meaningful Interest Coverage only. |
PDLI'
s Interest Coverage Range Over the Past 10 Years
Min: 4.85 Med: 12.37 Max: 19.15 Current: 5.1 |
| Piotroski F-Score: 3 |
|
| Altman Z-Score: 2.69 |
|
| Beneish M-Score: -1.84 |
|
| WACC vs ROIC |
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
| vs
industry |
vs
history |
||
|---|---|---|---|
| Operating Margin % | 40.59 |
PDLI's Operating Margin % is ranked higher than
95% of the 792 Companies in the Global Biotechnology industry. ( Industry Median: -113.97 vs. PDLI: 40.59 ) Ranked among companies with meaningful Operating Margin % only. |
PDLI'
s Operating Margin % Range Over the Past 10 Years
Min: 40.59 Med: 93.2 Max: 94.93 Current: 40.59 |
| Net Margin % | -32.35 |
PDLI's Net Margin % is ranked higher than
61% of the 792 Companies in the Global Biotechnology industry. ( Industry Median: -111.91 vs. PDLI: -32.35 ) Ranked among companies with meaningful Net Margin % only. |
PDLI'
s Net Margin % Range Over the Past 10 Years
Min: -32.35 Med: 55.8 Max: 60.49 Current: -32.35 |
| ROE % | -8.36 |
PDLI's ROE % is ranked higher than
72% of the 989 Companies in the Global Biotechnology industry. ( Industry Median: -42.82 vs. PDLI: -8.36 ) Ranked among companies with meaningful ROE % only. |
PDLI'
s ROE % Range Over the Past 10 Years
Min: -8.36 Med: 72.89 Max: 1166.18 Current: -8.36 |
| ROA % | -5.81 |
PDLI's ROA % is ranked higher than
74% of the 1084 Companies in the Global Biotechnology industry. ( Industry Median: -34.77 vs. PDLI: -5.81 ) Ranked among companies with meaningful ROA % only. |
PDLI'
s ROA % Range Over the Past 10 Years
Min: -5.81 Med: 38.25 Max: 77.05 Current: -5.81 |
| ROC (Joel Greenblatt) % | -504.56 |
PDLI's ROC (Joel Greenblatt) % is ranked higher than
51% of the 1036 Companies in the Global Biotechnology industry. ( Industry Median: -521.46 vs. PDLI: -504.56 ) Ranked among companies with meaningful ROC (Joel Greenblatt) % only. |
PDLI'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -504.56 Med: 82080.42 Max: 1198273.12 Current: -504.56 |
| 3-Year Revenue Growth Rate | -14.40 |
PDLI's 3-Year Revenue Growth Rate is ranked lower than
66% of the 651 Companies in the Global Biotechnology industry. ( Industry Median: 1.10 vs. PDLI: -14.40 ) Ranked among companies with meaningful 3-Year Revenue Growth Rate only. |
PDLI'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -22 Med: 13.4 Max: 65.5 Current: -14.4 |
| 3-Year EBITDA Growth Rate | -22.00 |
PDLI's 3-Year EBITDA Growth Rate is ranked lower than
75% of the 802 Companies in the Global Biotechnology industry. ( Industry Median: 4.60 vs. PDLI: -22.00 ) Ranked among companies with meaningful 3-Year EBITDA Growth Rate only. |
PDLI'
s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0 Med: -15 Max: 202.9 Current: -22 |
| 3-Year EPS without NRI Growth Rate | -27.50 |
PDLI's 3-Year EPS without NRI Growth Rate is ranked lower than
82% of the 763 Companies in the Global Biotechnology industry. ( Industry Median: 5.70 vs. PDLI: -27.50 ) Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only. |
PDLI'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0 Med: -43.2 Max: 89.5 Current: -27.5 |
| Chuck Royce 4,302 sh (New) Jim Simons 11,131,786 sh (+3.99%) Charles Brandes 1,112,679 sh (+0.48%) | First Eagle Investment 2,800 sh (unchged) | Barrow, Hanley, Mewhinney & Strauss 23,201 sh (-8.61%) |
| Pioneer Investments 20,000 sh (New) Chuck Royce 5,015 sh (+16.57%) | First Eagle Investment 2,800 sh (unchged) | Barrow, Hanley, Mewhinney & Strauss Sold Out Charles Brandes 1,100,518 sh (-1.09%) Jim Simons 10,284,454 sh (-7.61%) |
| Paul Tudor Jones 21,351 sh (New) | Pioneer Investments 20,000 sh (unchged) | First Eagle Investment Sold Out Jim Simons 9,648,854 sh (-6.18%) Chuck Royce 4,622 sh (-7.84%) Charles Brandes 820,741 sh (-25.42%) |
| Caxton Associates 45,069 sh (New) Chuck Royce 8,036 sh (+73.86%) Jim Simons 9,688,354 sh (+0.41%) | Pioneer Investments 20,000 sh (unchged) | Paul Tudor Jones Sold Out Charles Brandes 272,811 sh (-66.76%) |
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
| Guru | Date | Trades | Impact to Portfolio | Price Range * (?) | Current Price | Change from Average | Current Shares | |
|---|---|---|---|---|---|---|---|---|
| Charles Brandes | 2018-06-30 | Reduce -66.76% | 0.03% | $2.3 - $3.12 | $ 2.43 | -13% | 272,811 |  |
| Charles Brandes | 2018-03-31 | Reduce -25.42% | 0.02% | $2.39 - $3.09 | $ 2.43 | -11% | 820,741 | |
| First Eagle Investment | 2018-03-31 | Sold Out | $2.39 - $3.09 | $ 2.43 | -11% | 0 | | |
| Charles Brandes | 2017-12-31 | Reduce -1.09% | $2.74 - $3.51 | $ 2.43 | -21% | 1,100,518 | | |
| Barrow, Hanley, Mewhinney & Strauss | 2017-12-31 | Sold Out | $2.74 - $3.51 | $ 2.43 | -21% | 0 | | |
| Charles Brandes | 2017-09-30 | Add 0.48% | $2.17 - $3.4 | $ 2.43 | -12% | 1,112,679 | | |
| Barrow, Hanley, Mewhinney & Strauss | 2017-09-30 | Reduce -8.61% | $2.17 - $3.4 | $ 2.43 | -12% | 23,201 | |
More recent guru trades are included for Premium Members only!! More recent guru trades are included for USA Subscribe Members only!! What is Peter Lynch Charts )| Industry: | Biotechnology » Biotechnology NAICS: 325412 SIC: 2836 | |
|---|---|---|
| Compare: | SHSE:603229, NAS:SVA, XKRX:182400, TSX:AUP, XKRX:053030, NAS:AKBA, SZSE:002604, XMCE:PHM, SZSE:002566, XPAR:IPH, NAS:OBSV, NAS:PRTA, NAS:CYTK, NAS:VCEL, NAS:SIGA, BSP:GBIO33, NAS:CNCE, ASX:CUV, OCSE:ZEAL, XKRX:196170 » details | |
| Traded in other countries: | PDL.Germany, | |
| Headquarter Location: | USA |
| vs
industry |
vs
history |
||
|---|---|---|---|
| Forward PE Ratio | 10.56 |
PDLI's Forward PE Ratio is ranked higher than
96% of the 77 Companies in the Global Biotechnology industry. ( Industry Median: 28.41 vs. PDLI: 10.56 ) Ranked among companies with meaningful Forward PE Ratio only. |
N/A |
| PB Ratio | 0.48 |
PDLI's PB Ratio is ranked higher than
98% of the 962 Companies in the Global Biotechnology industry. ( Industry Median: 4.10 vs. PDLI: 0.48 ) Ranked among companies with meaningful PB Ratio only. |
PDLI'
s PB Ratio Range Over the Past 10 Years
Min: 0.43 Med: 1.71 Max: 38.99 Current: 0.48 |
| PS Ratio | 1.76 |
PDLI's PS Ratio is ranked higher than
90% of the 726 Companies in the Global Biotechnology industry. ( Industry Median: 9999.00 vs. PDLI: 1.76 ) Ranked among companies with meaningful PS Ratio only. |
PDLI'
s PS Ratio Range Over the Past 10 Years
Min: 0.87 Med: 2.87 Max: 15.85 Current: 1.76 |
| EV-to-EBIT | -1.55 |
PDLI's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies in the Global Biotechnology industry. ( Industry Median: 22.17 vs. PDLI: -1.55 ) Ranked among companies with meaningful EV-to-EBIT only. |
PDLI'
s EV-to-EBIT Range Over the Past 10 Years
Min: -2.6 Med: 3.3 Max: 10.5 Current: -1.55 |
| EV-to-EBITDA | -3.71 |
PDLI's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies in the Global Biotechnology industry. ( Industry Median: 18.08 vs. PDLI: -3.71 ) Ranked among companies with meaningful EV-to-EBITDA only. |
PDLI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.2 Med: 3.2 Max: 7.8 Current: -3.71 |
| EV-to-Revenue | 0.39 |
PDLI's EV-to-Revenue is ranked higher than
99% of the 771 Companies in the Global Biotechnology industry. ( Industry Median: 13.69 vs. PDLI: 0.39 ) Ranked among companies with meaningful EV-to-Revenue only. |
PDLI'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.2 Med: 3.2 Max: 11.5 Current: 0.39 |
| Shiller PE Ratio | 2.07 |
PDLI's Shiller PE Ratio is ranked higher than
93% of the 86 Companies in the Global Biotechnology industry. ( Industry Median: 42.91 vs. PDLI: 2.07 ) Ranked among companies with meaningful Shiller PE Ratio only. |
PDLI'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 1.78 Med: 3.76 Max: 209.25 Current: 2.07 |
| Current Ratio | 11.13 |
PDLI's Current Ratio is ranked higher than
79% of the 1074 Companies in the Global Biotechnology industry. ( Industry Median: 4.46 vs. PDLI: 11.13 ) Ranked among companies with meaningful Current Ratio only. |
PDLI'
s Current Ratio Range Over the Past 10 Years
Min: 0.26 Med: 9.88 Max: 76.07 Current: 11.13 |
| Quick Ratio | 10.80 |
PDLI's Quick Ratio is ranked higher than
79% of the 1074 Companies in the Global Biotechnology industry. ( Industry Median: 4.18 vs. PDLI: 10.80 ) Ranked among companies with meaningful Quick Ratio only. |
PDLI'
s Quick Ratio Range Over the Past 10 Years
Min: 0.26 Med: 9.76 Max: 76.07 Current: 10.8 |
| Days Inventory | 92.64 |
PDLI's Days Inventory is ranked higher than
62% of the 481 Companies in the Global Biotechnology industry. ( Industry Median: 125.55 vs. PDLI: 92.64 ) Ranked among companies with meaningful Days Inventory only. |
PDLI'
s Days Inventory Range Over the Past 10 Years
Min: 71.9 Med: 100.69 Max: 129.48 Current: 92.64 |
| Days Sales Outstanding | 34.10 |
PDLI's Days Sales Outstanding is ranked higher than
76% of the 668 Companies in the Global Biotechnology industry. ( Industry Median: 64.17 vs. PDLI: 34.10 ) Ranked among companies with meaningful Days Sales Outstanding only. |
PDLI'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.21 Med: 0.6 Max: 68.46 Current: 34.1 |
| Days Payable | 84.27 |
PDLI's Days Payable is ranked higher than
57% of the 536 Companies in the Global Biotechnology industry. ( Industry Median: 63.91 vs. PDLI: 84.27 ) Ranked among companies with meaningful Days Payable only. |
PDLI'
s Days Payable Range Over the Past 10 Years
Min: 84.27 Med: 433.23 Max: 629.97 Current: 84.27 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| 3-Year Dividend Growth Rate | -100.00 |
PDLI's 3-Year Dividend Growth Rate is ranked lower than
83% of the 86 Companies in the Global Biotechnology industry. ( Industry Median: 6.30 vs. PDLI: -100.00 ) Ranked among companies with meaningful 3-Year Dividend Growth Rate only. |
PDLI'
s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0 Med: 0 Max: -45 Current: -100 |
| 3-Year Average Share Buyback Ratio | 1.80 |
PDLI's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 857 Companies in the Global Biotechnology industry. ( Industry Median: -13.40 vs. PDLI: 1.80 ) Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only. |
PDLI'
s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -7.9 Med: -5.5 Max: 1.8 Current: 1.8 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| Price-to-Net-Cash | 2.19 |
PDLI's Price-to-Net-Cash is ranked higher than
85% of the 613 Companies in the Global Biotechnology industry. ( Industry Median: 7.29 vs. PDLI: 2.19 ) Ranked among companies with meaningful Price-to-Net-Cash only. |
PDLI'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.12 Med: 13.41 Max: 205.5 Current: 2.19 |
| Price-to-Net-Current-Asset-Value | 1.29 |
PDLI's Price-to-Net-Current-Asset-Value is ranked higher than
93% of the 745 Companies in the Global Biotechnology industry. ( Industry Median: 6.45 vs. PDLI: 1.29 ) Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only. |
PDLI'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.1 Med: 4.84 Max: 71.33 Current: 1.29 |
| Price-to-Tangible-Book | 1.10 |
PDLI's Price-to-Tangible-Book is ranked higher than
93% of the 894 Companies in the Global Biotechnology industry. ( Industry Median: 5.32 vs. PDLI: 1.10 ) Ranked among companies with meaningful Price-to-Tangible-Book only. |
PDLI'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.86 Med: 2.67 Max: 47.78 Current: 1.1 |
| Price-to-Intrinsic-Value-Projected-FCF | 0.16 | ||
| Price-to-Median-PS-Value | 0.61 |
PDLI's Price-to-Median-PS-Value is ranked higher than
72% of the 678 Companies in the Global Biotechnology industry. ( Industry Median: 0.92 vs. PDLI: 0.61 ) Ranked among companies with meaningful Price-to-Median-PS-Value only. |
PDLI'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.37 Med: 3.77 Max: 32.21 Current: 0.61 |
| Earnings Yield (Greenblatt) % | -64.92 |
PDLI's Earnings Yield (Greenblatt) % is ranked lower than
89% of the 1081 Companies in the Global Biotechnology industry. ( Industry Median: -7.73 vs. PDLI: -64.92 ) Ranked among companies with meaningful Earnings Yield (Greenblatt) % only. |
PDLI'
s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -97.29 Med: 29.7 Max: 265.1 Current: -64.92 |
| Forward Rate of Return (Yacktman) % | 28.97 |
PDLI's Forward Rate of Return (Yacktman) % is ranked higher than
94% of the 135 Companies in the Global Biotechnology industry. ( Industry Median: 11.41 vs. PDLI: 28.97 ) Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only. |
PDLI'
s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -8.7 Med: 18.8 Max: 71.3 Current: 28.97 |
| Revenue (TTM) (Mil) $ | 209.05 |
|---|---|
| EPS (TTM) $ | -0.46 |
| Beta | 0.11 |
| Volatility | 36.34% |
| 52-Week Range $ | 2.25 - 3.55 |
| Shares Outstanding (Mil) | 145.40 |
| Dec18 | Dec19 | |
|---|---|---|
| Revenue (Mil $) | 176 | 145 |
| EBIT (Mil $) | ||
| EBITDA (Mil $) | 54 | 39 |
| EPS ($) | -0.60 | 0.13 |
| EPS without NRI ($) | -0.60 | 0.13 |
| EPS Growth Rate (Future 3Y To 5Y Estimate) | N/A | |
| Dividends per Share ($) | ||
|
| Is PDL BioPharma (PDLI) a Great Stock for Value Investors? Sep 21 2018 - ZACKS |
GF Chat
Excel Add-In GURUF
API
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
My Gurus
Email Alerts
Stock PDF
RSS
Website
Filings
Manual of Stocks™ Web APP